Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season.

Publication ,  Journal Article
Grohskopf, LA; Sokolow, LZ; Fry, AM; Walter, EB; Jernigan, DB
Published in: MMWR Morb Mortal Wkly Rep
June 8, 2018

Intranasally administered live attenuated influenza vaccine (LAIV) was initially licensed in the United States in 2003 as a trivalent formulation (LAIV3) (FluMist, MedImmune, LLC). Quadrivalent live attenuated influenza vaccine (LAIV4) (FluMist Quadrivalent, MedImmune) has been licensed in the United States since 2012 and was first available during the 2013-14 influenza season, replacing LAIV3. During the 2016-17 and 2017-18 influenza seasons, the Advisory Committee on Immunization Practices (ACIP) recommended that LAIV4 not be used because of concerns about low effectiveness against influenza A(H1N1)pdm09-like viruses circulating in the United States during the 2013-14 and 2015-16 seasons (1,2). On February 21, 2018, ACIP recommended that LAIV4 be an option for influenza vaccination of persons for whom it is appropriate for the 2018-19 season (3). This document provides an overview of the information discussed in the decision-making process leading to this recommendation. A description of methodology and data reviewed will be included in the background materials that will supplement the 2018-19 ACIP Influenza Recommendations, which will replace the 2017-18 ACIP influenza statement (2), and which will also contain guidance for the use of LAIV4.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

MMWR Morb Mortal Wkly Rep

DOI

EISSN

1545-861X

Publication Date

June 8, 2018

Volume

67

Issue

22

Start / End Page

643 / 645

Location

United States

Related Subject Headings

  • Vaccines, Attenuated
  • United States
  • Seasons
  • Randomized Controlled Trials as Topic
  • Pandemics
  • Influenza, Human
  • Influenza Vaccines
  • Influenza A Virus, H1N1 Subtype
  • Immunization Schedule
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Grohskopf, L. A., Sokolow, L. Z., Fry, A. M., Walter, E. B., & Jernigan, D. B. (2018). Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season. MMWR Morb Mortal Wkly Rep, 67(22), 643–645. https://doi.org/10.15585/mmwr.mm6722a5
Grohskopf, Lisa A., Leslie Z. Sokolow, Alicia M. Fry, Emmanuel B. Walter, and Daniel B. Jernigan. “Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season.MMWR Morb Mortal Wkly Rep 67, no. 22 (June 8, 2018): 643–45. https://doi.org/10.15585/mmwr.mm6722a5.
Grohskopf LA, Sokolow LZ, Fry AM, Walter EB, Jernigan DB. Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season. MMWR Morb Mortal Wkly Rep. 2018 Jun 8;67(22):643–5.
Grohskopf, Lisa A., et al. “Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season.MMWR Morb Mortal Wkly Rep, vol. 67, no. 22, June 2018, pp. 643–45. Pubmed, doi:10.15585/mmwr.mm6722a5.
Grohskopf LA, Sokolow LZ, Fry AM, Walter EB, Jernigan DB. Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season. MMWR Morb Mortal Wkly Rep. 2018 Jun 8;67(22):643–645.

Published In

MMWR Morb Mortal Wkly Rep

DOI

EISSN

1545-861X

Publication Date

June 8, 2018

Volume

67

Issue

22

Start / End Page

643 / 645

Location

United States

Related Subject Headings

  • Vaccines, Attenuated
  • United States
  • Seasons
  • Randomized Controlled Trials as Topic
  • Pandemics
  • Influenza, Human
  • Influenza Vaccines
  • Influenza A Virus, H1N1 Subtype
  • Immunization Schedule
  • Humans